Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a one year consensus price objective of $27.25 for the company and are predicting that the company will post ($0.55) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Dipexium Pharmaceuticals an industry rank of 97 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised shares of Dipexium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 14th.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Fund Advisors raised its position in shares of Dipexium Pharmaceuticals by 19.6% in the second quarter. BlackRock Fund Advisors now owns 15,674 shares of the company’s stock worth $155,000 after buying an additional 2,568 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Dipexium Pharmaceuticals by 51.5% in the first quarter. Renaissance Technologies LLC now owns 25,900 shares of the company’s stock worth $246,000 after buying an additional 8,800 shares during the last quarter. Raymond James & Associates acquired a new position in shares of Dipexium Pharmaceuticals during the second quarter worth about $312,000. Geode Capital Management LLC raised its position in shares of Dipexium Pharmaceuticals by 9.1% in the first quarter. Geode Capital Management LLC now owns 33,170 shares of the company’s stock worth $315,000 after buying an additional 2,759 shares during the last quarter. Finally, Falcon Point Capital LLC raised its position in shares of Dipexium Pharmaceuticals by 12.5% in the second quarter. Falcon Point Capital LLC now owns 38,833 shares of the company’s stock worth $385,000 after buying an additional 4,315 shares during the last quarter. Hedge funds and other institutional investors own 24.78% of the company’s stock.
Dipexium Pharmaceuticals (NASDAQ:DPRX) opened at 15.53 on Wednesday. The company’s market cap is $161.48 million. Dipexium Pharmaceuticals has a 52-week low of $6.04 and a 52-week high of $16.32. The company has a 50-day moving average of $13.03 and a 200 day moving average of $10.91.
Dipexium Pharmaceuticals (NASDAQ:DPRX) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.02. Equities research analysts predict that Dipexium Pharmaceuticals will post ($2.10) EPS for the current year.
Dipexium Pharmaceuticals Company Profile
Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.